Literature DB >> 17914730

Measuring health-related quality of life in MSA: the MSA-QoL.

Anette Schrag1, Caroline Selai, Chris Mathias, Philip Low, Jeremy Hobart, Niall Brady, Niall Patrick Quinn.   

Abstract

The objective of this study was to develop a new patient-reported outcome measure for patients with multiple system atrophy (MSA) and to test its psychometric properties. There were three stages. First, a pool of potential scale items was generated from in-depth patient interviews. Second, these items were administered, in the form of a questionnaire, to a sample of people with MSA and traditional psychometric methods used to develop a rating scale satisfying standard criteria for reliability and validity. Third, the psychometric properties of the rating scale were examined in a second sample. In stage one, a pool of 105 items was generated from 20 patient interviews. In stage two, a scale with three subscales (motor, 14 items; nonmotor, 12 items; emotional/social functioning, 14 items), satisfying standard criteria for reliability and validity, was developed from the response data of 317 patients with MSA (response rate 71%). In stage three, the scale was examined in 286 people with MSA. Missing data were low, scores in both subscales were evenly distributed, and floor and ceiling effects were small. Reliability was high (Cronbach's alpha 0.83-0.93; test-retest ICC 0.88-0.92). Validity was supported by the interscale correlations (r = 0.47-0.59), known group differences, and the magnitude and pattern of correlations with four other rating scales, disease severity, and disease duration. In conclusion, the patient-rated MSA health-related Quality of life scale (MSA-QoL) may be a suitable patient-reported scale for use in clinical trials and studies in MSA. 2007 Movement Disorder Society

Entities:  

Mesh:

Year:  2007        PMID: 17914730     DOI: 10.1002/mds.21649

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  22 in total

Review 1.  Multiple system atrophy: a clinical and neuropathological perspective.

Authors:  Kiren Ubhi; Phillip Low; Eliezer Masliah
Journal:  Trends Neurosci       Date:  2011-09-29       Impact factor: 13.837

2.  Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges.

Authors:  Jose-Alberto Palma; Horacio Kaufmann
Journal:  Semin Neurol       Date:  2020-09-09       Impact factor: 3.420

3.  Comparison of Different Symptom Assessment Scales for Multiple System Atrophy.

Authors:  Masaaki Matsushima; Ichiro Yabe; Koji Oba; Ken Sakushima; Yasunori Mito; Asako Takei; Hideki Houzen; Kazufumi Tsuzaka; Kazuto Yoshida; Yasunori Maruo; Hidenao Sasaki
Journal:  Cerebellum       Date:  2016-04       Impact factor: 3.847

4.  Clinical features and autonomic testing predict survival in multiple system atrophy.

Authors:  Elizabeth A Coon; David M Sletten; Mariana D Suarez; Jay N Mandrekar; J Eric Ahlskog; James H Bower; Joseph Y Matsumoto; Michael H Silber; Eduardo E Benarroch; Robert D Fealey; Paola Sandroni; Phillip A Low; Wolfgang Singer
Journal:  Brain       Date:  2015-09-13       Impact factor: 13.501

Review 5.  Alzheimer's disease drug development: old problems require new priorities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-12       Impact factor: 4.388

6.  Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure.

Authors:  Axel Lipp; Paola Sandroni; J Eric Ahlskog; Robert D Fealey; Kurt Kimpinski; Valeria Iodice; Tonette L Gehrking; Stephen D Weigand; David M Sletten; Jade A Gehrking; Kim K Nickander; Wolfgang Singer; Demetrius M Maraganore; Sid Gilman; Gregor K Wenning; Clifford W Shults; Phillip A Low
Journal:  Arch Neurol       Date:  2009-06

7.  Development and validation of a carers quality-of-life questionnaire for parkinsonism (PQoL Carers).

Authors:  Marios Pillas; Caroline Selai; Niall P Quinn; Andrew Lees; Irene Litvan; Anthony Lang; James Bower; David Burn; Philip Low; Anette Schrag
Journal:  Qual Life Res       Date:  2015-08-12       Impact factor: 4.147

Review 8.  Multiple system atrophy: experimental models and reality.

Authors:  Cassia Overk; Edward Rockenstein; Elvira Valera; Nadia Stefanova; Gregor Wenning; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2017-10-20       Impact factor: 17.088

9.  [MSA-QoL: disease-specific questionnaire to assess health-related quality of life in multiple system atrophy: validation of the German translation].

Authors:  F Krismer; S Duerr; M Minnerop; T Klockgether; M Stamelou; K M Eggert; W H Oertel; A Schrag; W Poewe; G K Wenning
Journal:  Nervenarzt       Date:  2013-06       Impact factor: 1.214

Review 10.  Current Concepts in the Treatment of Multiple System Atrophy.

Authors:  Santiago Perez-Lloret; Olivier Flabeau; Pierre-Olivier Fernagut; Anne Pavy-Le Traon; María Verónica Rey; Alexandra Foubert-Samier; Francois Tison; Olivier Rascol; Wassilios G Meissner
Journal:  Mov Disord Clin Pract       Date:  2015-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.